US 9752147
RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions
granted A61KA61K31/713A61P
Quick answer
US patent 9752147 (RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions) held by Arrowhead Pharmaceuticals, Inc. expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Arrowhead Pharmaceuticals, Inc.
- Grant date
- Tue Sep 05 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K31/713, A61P, A61P27/02, A61P27/06